C8orf34-AS1: A Potential Drug Target and Biomarker for the Treatment of Fibrosis and other Chronic Diseases

Target Name: C8orf34-AS1

NCBI ID: G286189

C8orf34-AS1

Other Name(s): C8orf34 antisense RNA 1

C8orf34-AS1: A Potential Drug Target and Biomarker for the Treatment of Fibrosis and other Chronic Diseases

Fibrosis is a complex biological process that involves the gradual accumulation of extracellular matrix (ECM) components, leading to the replacement of normal tissues with scar tissue. Fibrosis can occur in various organs, including lungs, hearts, kidneys, and intestines, and can lead to chronic diseases such as chronic obstructive pulmonary disease (COPD), heart failure, and kidney failure. Currently, there are limited treatment options available for the treatment of fibrosis, and the search for new drugs and biomarkers is ongoing.

C8orf34-AS1: A Potential Drug Target and Biomarker

C8orf34-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of fibrosis. The molecule is derived from the genomic region encoding the protein C8orf34, which is a non-protein coding RNA molecule that has been shown to play a role in the regulation of matrix metalloproteinase (MMP) enzymes, which are involved in the breakdown of ECM.

Expression of C8orf34-AS1 in fibrotic tissues

To investigate the expression of C8orf34-AS1 in fibrotic tissues, researchers have used RNA sequencing (RNA-seq) and gene expression analysis techniques. The results of these studies have shown that C8orf34-AS1 is highly expressed in fibrotic tissues, including lungs, hearts, kidneys, and intestines. The expression of C8orf34-AS1 has been associated with the development of fibrosis and the progression of fibrotic diseases.

C8orf34-AS1 as a biomarker for fibrosis

C8orf34-AS1 has also been investigated as a potential biomarker for fibrosis. Fibrotic diseases are characterized by the accumulation of extracellular matrix components, leading to the replacement of normal tissues with scar tissue. The accumulation of ECM components is associated with the activation of MMP enzymes, which can lead to the breakdown of ECM components and the progression of fibrosis.

C8orf34-AS1 has been shown to be involved in the regulation of MMP enzymes, which suggests that it may play a role in the control of fibrosis. Additionally, the expression of C8orf34-AS1 has been associated with the development of fibrotic diseases, including fibrosis of the lungs, heart failure, and kidney failure. These findings suggest that C8orf34-AS1 may be a useful biomarker for the diagnosis and treatment of fibrosis.

C8orf34-AS1 as a drug target

C8orf34-AS1 has also been identified as a potential drug target for the treatment of fibrosis. Fibrotic diseases are characterized by the accumulation of extracellular matrix components, leading to the replacement of normal tissues with scar tissue. The accumulation of ECM components is associated with the activation of MMP enzymes, which can lead to the breakdown of ECM components and the progression of fibrosis.

C8orf34-AS1 has been shown to be involved in the regulation of MMP enzymes, which suggests that it may play a role in the control of fibrosis. Additionally, the expression of C8orf34-AS1 has been associated with the development of fibrotic diseases, including fibrosis of the lungs, heart failure, and kidney failure. These findings suggest that C8orf34-AS1 may be a useful drug target for the treatment of fibrosis.

Conclusion

C8orf34-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of fibrosis. The molecule is derived from the genomic region encoding the protein C8orf34, which is involved in the regulation of matrix metalloproteinase (MMP) enzymes.

Expression of C8orf34-AS1 has been shown to be highly expressed in fibrotic tissues, including lungs, hearts, kidneys, and intestines. The expression of C8orf34-AS1 has been associated with the development of fibrosis and the progression of fibrotic diseases. Additionally, C8orf34-AS1 has been shown to be involved in the regulation of MMP enzymes, which suggests that it may play a role in the control of fibrosis.

C8orf34-AS1 may also be a useful biomarker for the diagnosis and treatment of fibrosis, as well as a potential drug target for the treatment of fibrosis. Further research is needed to confirm these findings and to develop new treatments for fibrosis based on C8orf34-AS1.

Protein Name: C8orf34 Antisense RNA 1

The "C8orf34-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C8orf34-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets